{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:09:45Z","timestamp":1792087785185,"version":"4.4.0"},"reference-count":113,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T00:00:00Z","timestamp":1728345600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty liver disease, continues to rise with rapid economic development and poses significant challenges to human health. No effective drugs are clinically approved. MASLD is regarded as a multifaceted pathological process encompassing aberrant lipid metabolism, insulin resistance, inflammation, gut microbiota imbalance, apoptosis, fibrosis, and cirrhosis. In recent decades, herbal medicines have gained increasing attention as potential therapeutic agents for the prevention and treatment of MASLD, due to their good tolerance, high efficacy, and low toxicity. In this review, we summarize the pathological mechanisms of MASLD; emphasis is placed on the anti-MASLD mechanisms of Chinese herbal formula (CHF), especially their effects on improving lipid metabolism, inflammation, intestinal flora, and fibrosis. Our goal is to better understand the pharmacological mechanisms of CHF to inform research on the development of new drugs for the treatment of MASLD.<\/jats:p>","DOI":"10.3389\/fmed.2024.1476419","type":"journal-article","created":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T04:33:01Z","timestamp":1728361981000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":16,"title":["Chinese herbal formula in the treatment of metabolic dysfunction-associated steatotic liver disease: current evidence and practice"],"prefix":"10.3389","volume":"11","author":[{"given":"Shao-Hong","family":"Tao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Qing","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Mei","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Bo","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Ning","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,10,8]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.cld.2015.10.001","article-title":"Epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in the United States and the rest of the world","volume":"20","author":"Sayiner","year":"2016","journal-title":"Clin Liver Dis"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.jhep.2023.03.040","article-title":"Global incidence of non-alcoholic fatty liver disease: a systematic review and meta-analysis of 63 studies and 1,201,807 persons","volume":"79","author":"Le","year":"2023","journal-title":"J Hepatol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"E93","DOI":"10.1097\/hep.0000000000000696","article-title":"Reply: a multi-society Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Lazarus","year":"2024","journal-title":"Hepatology"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1411802","DOI":"10.3389\/fnut.2024.1411802","article-title":"Comparing similarities and differences between Nafld, Mafld, and Masld in the general U.S. population","volume":"11","author":"Zou","year":"2024","journal-title":"Front Nutr"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"101179","DOI":"10.1097\/hep.0000000000000705","article-title":"Reply: \u2018From Nafld to Masld: promise and pitfalls of a new definition\u2019\u2020","volume":"29","author":"Mary","year":"2023","journal-title":"Hepatology"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/s41575-019-0144-8","article-title":"Past, present and future perspectives in nonalcoholic fatty liver disease","volume":"16","author":"Sanyal","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.freeradbiomed.2015.03.024","article-title":"Cox-2 is involved in vascular oxidative stress and endothelial dysfunction of renal interlobar arteries from obese Zucker rats","volume":"84","author":"Mu\u00f1oz","year":"2015","journal-title":"Free Radic Biol Med"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1016\/j.jhep.2012.12.003","article-title":"A 360-degree overview of paediatric Nafld: recent insights","volume":"58","author":"Nobili","year":"2013","journal-title":"J Hepatol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.jhep.2014.10.039","article-title":"Molecular mechanism of Ppar\u03b1 action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease","volume":"62","author":"Pawlak","year":"2015","journal-title":"J Hepatol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"230","DOI":"10.14218\/jcth.2015.00019","article-title":"Treatment of nonalcoholic fatty liver disease: the role of medical, surgical, and endoscopic weight loss","volume":"3","author":"Popov","year":"2015","journal-title":"J Clin Transl Hepatol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"104686","DOI":"10.1016\/j.jff.2021.104686","article-title":"Arjunolic acid from Cyclocarya Paliurus ameliorates nonalcoholic fatty liver disease in mice via activating Sirt1\/Ampk, triggering autophagy and improving gut barrier function","volume":"86","author":"Zheng","year":"2021","journal-title":"J Funct Foods"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/s41575-023-00800-4","article-title":"Lifestyle interventions in nonalcoholic fatty liver disease","volume":"20","author":"Younossi","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1007\/s13105-023-00954-4","article-title":"Metabolic dysfunction-associated fatty liver disease (Mafld): an update of the recent advances in pharmacological treatment","volume":"79","author":"Sangro","year":"2023","journal-title":"J Physiol Biochem"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"3048","DOI":"10.3748\/wjg.v29.i20.3048","article-title":"Hericium Erinaceus, a medicinal fungus with a centuries-old history: evidence in gastrointestinal diseases","volume":"29","author":"Gravina","year":"2023","journal-title":"World J Gastroenterol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s12985-015-0339-8","article-title":"The Chinese herb-derived Sparstolonin B suppresses Hiv-1 transcription","volume":"12","author":"Deng","year":"2015","journal-title":"Virol J"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"13659","DOI":"10.3390\/molecules200813659","article-title":"Steroidal Saponins from the roots and rhizomes of Tupistra Chinensis","volume":"20","author":"Li","year":"2015","journal-title":"Molecules"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1002\/hep.510270601","article-title":"Hepatic steatosis: innocent bystander or guilty party?","volume":"27","author":"Day","year":"1998","journal-title":"Hepatology"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1002\/hep.24001","article-title":"Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis","volume":"52","author":"Tilg","year":"2010","journal-title":"Hepatology"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"10.1097\/hep.0000000000000735","DOI":"10.1097\/hep.0000000000000735","article-title":"Metabolic dysfunction-associated steatotic liver disease and the heart","author":"Driessen","year":"2023","journal-title":"Hepatology"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.jhep.2016.03.006","article-title":"Tumor necrosis factor receptor-associated factor 5 (Traf5) acts as an essential negative regulator of hepatic steatosis","volume":"65","author":"Gao","year":"2016","journal-title":"J Hepatol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1007\/s10620-016-4054-0","article-title":"Role of dietary fructose and hepatic De novo lipogenesis in fatty liver disease","volume":"61","author":"Softic","year":"2016","journal-title":"Dig Dis Sci"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1172\/jci134165","article-title":"Insulin resistance drives hepatic De novo lipogenesis in nonalcoholic fatty liver disease","volume":"130","author":"Smith","year":"2020","journal-title":"J Clin Invest"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1294267","DOI":"10.3389\/fmed.2023.1294267","article-title":"Unmasking the enigma of lipid metabolism in metabolic dysfunction-associated steatotic liver disease: from mechanism to the clinic","volume":"10","author":"Rao","year":"2023","journal-title":"Front Med"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3390\/metabo14010012","article-title":"Lipid metabolism in metabolic-associated steatotic liver disease (Masld)","volume":"14","author":"Syed-Abdul","year":"2023","journal-title":"Meta"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1053\/j.gastro.2007.11.038","article-title":"Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease","volume":"134","author":"Fabbrini","year":"2008","journal-title":"Gastroenterology"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1146\/annurev-pathol-012615-044224","article-title":"Nonalcoholic fatty liver disease: pathogenesis and disease Spectrum","volume":"11","author":"Hardy","year":"2016","journal-title":"Ann Rev Pathol Mech Dis"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/978-981-10-8684-7_3","article-title":"Pathogenesis of Nash: how metabolic complications of overnutrition favour lipotoxicity and pro-inflammatory fatty liver disease","volume":"1061","author":"Farrell","year":"2018","journal-title":"Obesity Fatty Liver Liver Cancer"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1002\/hep.30429","article-title":"Modulation of insulin resistance in nonalcoholic fatty liver disease","volume":"70","author":"Khan","year":"2019","journal-title":"Hepatology"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.cmet.2012.04.001","article-title":"Inflammation and lipid signaling in the etiology of insulin resistance","volume":"15","author":"Glass","year":"2012","journal-title":"Cell Metab"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1136\/gutjnl-2011-300304","article-title":"Pharmacological inhibition of the chemokine Ccl2 (Mcp-1) diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury","volume":"61","author":"Baeck","year":"2012","journal-title":"Gut"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/s41575-018-0082-x","article-title":"The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis","volume":"16","author":"Kazankov","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"708978","DOI":"10.3389\/fimmu.2021.708978","article-title":"Hepatic macrophage as a key player in fatty liver disease","volume":"12","author":"Xu","year":"2021","journal-title":"Front Immunol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1007\/s10620-016-4049-x","article-title":"Innate immunity and inflammation in Nafld\/Nash","volume":"61","author":"Arrese","year":"2016","journal-title":"Dig Dis Sci"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1002\/path.4133","article-title":"Macrophage plasticity and polarization in tissue repair and remodelling","volume":"229","author":"Mantovani","year":"2013","journal-title":"J Pathol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1118449","DOI":"10.3389\/fimmu.2023.1118449","article-title":"Programmed cell death and lipid metabolism of macrophages in Nafld","volume":"14","author":"Xiao","year":"2023","journal-title":"Front Immunol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"627424","DOI":"10.3389\/fimmu.2020.627424","article-title":"Extracellular vesicles as inflammatory drivers in Nafld","volume":"11","author":"Srinivas","year":"2020","journal-title":"Front Immunol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.3390\/biom10111494","article-title":"Extracellular vesicles in the development of the non-alcoholic fatty liver disease: an update","volume":"10","author":"Dorairaj","year":"2020","journal-title":"Biomol Ther"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1002\/hep.26607","article-title":"M2 Kupffer cells promote M1 Kupffer cell apoptosis: a protective mechanism against alcoholic and nonalcoholic fatty liver disease","volume":"59","author":"Wan","year":"2014","journal-title":"Hepatology"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.jhep.2017.11.012","article-title":"Determinants of fibrosis progression and regression in Nash","volume":"68","author":"Schuppan","year":"2018","journal-title":"J Hepatol"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"641240","DOI":"10.3389\/fimmu.2021.641240","article-title":"Hepatic dendritic cells in the development and progression of metabolic steatohepatitis","volume":"12","author":"M\u00e9ndez-S\u00e1nchez","year":"2021","journal-title":"Front Immunol"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1002\/hep.26267","article-title":"Dendritic cells limit fibroinflammatory injury in nonalcoholic steatohepatitis in mice","volume":"58","author":"Henning","year":"2013","journal-title":"Hepatology"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s10020-019-0084-3","article-title":"Increased proteinase 3 and neutrophil elastase plasma concentrations are associated with non-alcoholic fatty liver disease (Nafld) and type 2 diabetes","volume":"25","author":"Mirea","year":"2019","journal-title":"Mol Med"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"S181","DOI":"10.14309\/00000434-201210001-00433","article-title":"Plasma myeloperoxidase levels correlate with the presence of fibrosis in patients with nonalcoholic fatty liver disease: 433","volume":"107","author":"Alkhouri","year":"2012","journal-title":"Off J Am Coll Gastroenterol ACG"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1089\/ars.2014.6108","article-title":"Myeloperoxidase\u2013hepatocyte\u2013stellate cell cross talk promotes hepatocyte injury and fibrosis in experimental nonalcoholic steatohepatitis","volume":"23","author":"Pulli","year":"2015","journal-title":"Antioxid Redox Signal"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1186\/s13287-022-02929-6","article-title":"The role of the immune system in the pathogenesis of Nafld and potential therapeutic impacts of mesenchymal stem cell-derived extracellular vesicles","volume":"13","author":"Moayedfard","year":"2022","journal-title":"Stem Cell Res Ther"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1111\/j.1478-3231.2011.02608.x","article-title":"Role of stress-induced Nkg2d ligands in liver diseases","volume":"32","author":"Kahraman","year":"2012","journal-title":"Liver Int"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/nri3495","article-title":"Mitogen-activated protein kinases in innate immunity","volume":"13","author":"Arthur","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"2852","DOI":"10.1038\/ncomms3852","article-title":"TRAF1 is a critical regulator of cerebral ischaemia\u2013reperfusion injury and neuronal death","volume":"4","author":"Lu","year":"2013","journal-title":"Nat Commun"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1016\/j.jhep.2016.02.002","article-title":"Targeting hepatic Traf1-Ask1 signaling to improve inflammation, insulin resistance, and hepatic steatosis","volume":"64","author":"Xiang","year":"2016","journal-title":"J Hepatol"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"e1467","DOI":"10.1038\/cddis.2014.411","article-title":"Traf1 is a key mediator for hepatic ischemia\/reperfusion injury","volume":"5","author":"Zhang","year":"2014","journal-title":"Cell Death Dis"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"11267","DOI":"10.1038\/ncomms11267","article-title":"The ubiquitin E3 ligase Traf6 exacerbates pathological cardiac hypertrophy via Tak1-dependent Signalling","volume":"7","author":"Ji","year":"2016","journal-title":"Nat Commun"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/nm.4453","article-title":"The deubiquitinating enzyme Tnfaip3 mediates inactivation of hepatic Ask1 and ameliorates nonalcoholic steatohepatitis","volume":"24","author":"Zhang","year":"2018","journal-title":"Nat Med"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1038\/nm.4290","article-title":"Targeting Casp8 and Fadd-like apoptosis regulator ameliorates nonalcoholic steatohepatitis in mice and nonhuman primates","volume":"23","author":"Wang","year":"2017","journal-title":"Nat Med"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.jhep.2016.03.008","article-title":"Dkk3 expression in hepatocytes defines susceptibility to liver steatosis and obesity","volume":"65","author":"Xie","year":"2016","journal-title":"J Hepatol"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1016\/j.jhep.2018.06.014","article-title":"Caspase recruitment domain 6 protects against hepatic ischemia\/reperfusion injury by suppressing Ask1","volume":"69","author":"Qin","year":"2018","journal-title":"J Hepatol"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1002\/hep.29257","article-title":"The novel intracellular protein Creg inhibits hepatic steatosis, obesity, and insulin resistance","volume":"66","author":"Zhang","year":"2017","journal-title":"Hepatology"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.cell.2018.01.007","article-title":"Tbk1 at the crossroads of inflammation and energy homeostasis in adipose tissue","volume":"172","author":"Zhao","year":"2018","journal-title":"Cell"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"11432","DOI":"10.1038\/ncomms11432","article-title":"Suppressor of Ikk\u025b is an essential negative regulator of pathological cardiac hypertrophy","volume":"7","author":"Deng","year":"2016","journal-title":"Nat Commun"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1002\/hep.26751","article-title":"Interferon regulatory factor 3 constrains Ikk\u03b2\/Nf-\u039ab signaling to alleviate hepatic steatosis and insulin resistance","volume":"59","author":"Wang","year":"2014","journal-title":"Hepatology"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1002\/hep.26368","article-title":"Interferon regulatory factor 9 protects against hepatic insulin resistance and steatosis in male mice","volume":"58","author":"Wang","year":"2013","journal-title":"Hepatology"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"5160","DOI":"10.1038\/ncomms6160","article-title":"Interferon regulatory factor 9 is critical for Neointima formation following vascular injury","volume":"5","author":"Zhang","year":"2014","journal-title":"Nat Commun"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.jhep.2014.08.022","article-title":"Interferon regulatory factor 9 is a key mediator of hepatic ischemia\/reperfusion injury","volume":"62","author":"Wang","year":"2015","journal-title":"J Hepatol"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1002\/hep.26749","article-title":"Adaptive immune responses triggered by oxidative stress contribute to hepatic inflammation in Nash","volume":"59","author":"Sutti","year":"2014","journal-title":"Hepatology"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.ccell.2014.09.003","article-title":"Metabolic activation of intrahepatic Cd8+ T cells and Nkt cells causes nonalcoholic steatohepatitis and liver Cancer via cross-talk with hepatocytes","volume":"26","author":"Wolf","year":"2014","journal-title":"Cancer Cell"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1007\/s10875-011-9571-1","article-title":"Altered phenotype and functionality of circulating immune cells characterize adult patients with nonalcoholic steatohepatitis","volume":"31","author":"Inzaugarat","year":"2011","journal-title":"J Clin Immunol"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/s41575-019-0210-2","article-title":"Adaptive immunity: an emerging player in the progression of Nafld","volume":"17","author":"Sutti","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1111\/j.1365-2249.2011.04471.x","article-title":"Interleukin-17 exacerbates hepatic steatosis and inflammation in non-alcoholic fatty liver disease","volume":"166","author":"Tang","year":"2011","journal-title":"Clin Exp Immunol"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1053\/j.gastro.2012.05.049","article-title":"Interleukin-17 signaling in inflammatory, Kupffer cells, and hepatic stellate cells exacerbates liver fibrosis in mice","volume":"143","author":"Meng","year":"2012","journal-title":"Gastroenterology"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"82","DOI":"10.3389\/fimmu.2019.00082","article-title":"The differential roles of T cells in non-alcoholic fatty liver disease and obesity","volume":"10","author":"Van Herck","year":"2019","journal-title":"Front Immunol"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"97","DOI":"10.4049\/jimmunol.1501175","article-title":"Progression from nonalcoholic fatty liver to nonalcoholic steatohepatitis is marked by a higher frequency of Th17 cells in the liver and an increased Th17\/resting regulatory T cell ratio in peripheral blood and in the liver","volume":"196","author":"Rau","year":"2016","journal-title":"J Immunol (Baltimore, Md: 1950)"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/j.jhep.2014.01.010","article-title":"Serum immunoglobulin levels predict fibrosis in patients with non-alcoholic fatty liver disease","volume":"60","author":"McPherson","year":"2014","journal-title":"J Hepatol"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1038\/nature24302","article-title":"Inflammation-induced Iga+ cells dismantle anti-liver cancer immunity","volume":"551","author":"Shalapour","year":"2017","journal-title":"Nature"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"31","DOI":"10.20517\/2394-5079.2022.34","article-title":"Alteration in immune function in patients with fatty liver disease","volume":"8","author":"Gregory","year":"2022","journal-title":"Hepatoma Res"},{"key":"ref74","doi-asserted-by":"publisher","first-page":"e003618","DOI":"10.1136\/jitc-2021-003618","article-title":"Intrahepatic inflammatory Iga+ Pd-L1high monocytes in hepatocellular carcinoma development and immunotherapy","volume":"10","author":"Sung","year":"2022","journal-title":"J Immunother Cancer"},{"key":"ref75","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2018\/9321643","article-title":"Gut microbiota as a driver of inflammation in nonalcoholic fatty liver disease","volume":"2018","author":"Bibb\u00f2","year":"2018","journal-title":"Mediat Inflamm"},{"key":"ref76","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jhep.2017.11.014","article-title":"Lipotoxicity and the gut-liver Axis in Nash pathogenesis","volume":"68","author":"Marra","year":"2018","journal-title":"J Hepatol"},{"key":"ref77","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1038\/nm.4185","article-title":"Signals from the gut microbiota to distant organs in physiology and disease","volume":"22","author":"Schroeder","year":"2016","journal-title":"Nat Med"},{"key":"ref78","doi-asserted-by":"publisher","first-page":"869446","DOI":"10.3389\/fphar.2022.869446","article-title":"Just drink a glass of water? Effects of bicarbonate-sulfate-calcium-magnesium water on the gut-liver axis","volume":"13","author":"Gravina","year":"2022","journal-title":"Front Pharmacol"},{"key":"ref79","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.clnesp.2023.07.008","article-title":"The use of bicarbonate-sulphate-calcium-magnesium and sodium-low drinkable water improves functional gastrointestinal symptoms in patients with non-alcoholic fatty liver disease: a prospective study","volume":"57","author":"Gravina","year":"2023","journal-title":"Clin Nutr ESPEN"},{"key":"ref80","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1038\/nrgastro.2013.149","article-title":"From Nafld to Nash to cirrhosis\u2014new insights into disease mechanisms","volume":"10","author":"Wree","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref81","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1038\/nrgastro.2010.172","article-title":"The role of the gut microbiota in nonalcoholic fatty liver disease","volume":"7","author":"Abu-Shanab","year":"2010","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref82","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.2353\/ajpath.2009.080999","article-title":"Increased hepatic myeloperoxidase activity in obese subjects with nonalcoholic steatohepatitis","volume":"175","author":"Rensen","year":"2009","journal-title":"Am J Pathol"},{"key":"ref83","doi-asserted-by":"publisher","first-page":"615978","DOI":"10.3389\/fmed.2021.615978","article-title":"Liver fibrosis in non-alcoholic fatty liver disease: from liver biopsy to non-invasive biomarkers in diagnosis and treatment","volume":"8","author":"Heyens","year":"2021","journal-title":"Front Med"},{"key":"ref84","doi-asserted-by":"publisher","first-page":"4831","DOI":"10.3748\/wjg.v29.i32.4831","article-title":"Non-alcoholic fatty liver disease: immunological mechanisms and current treatments","volume":"29","author":"Petagine","year":"2023","journal-title":"World J Gastroenterol"},{"key":"ref85","doi-asserted-by":"publisher","first-page":"858795","DOI":"10.3389\/fphar.2022.858795","article-title":"Multi-omics integration analysis identifies lipid disorder of a non-alcoholic fatty liver disease (Nafld) mouse model improved by Zexie-Baizhu decoction","volume":"13","author":"Cao","year":"2022","journal-title":"Front Pharmacol"},{"key":"ref86","doi-asserted-by":"publisher","first-page":"116081","DOI":"10.1016\/j.jep.2022.116081","article-title":"Si-Ni-san reduces lipid droplet deposition associated with decreased Yap1 in metabolic dysfunction-associated fatty liver disease","volume":"305","author":"Zheng","year":"2023","journal-title":"J Ethnopharmacol"},{"key":"ref87","doi-asserted-by":"publisher","first-page":"1026912","DOI":"10.3389\/fphar.2022.1026912","article-title":"Hepatoprotective effect of botanical drug formula on high-fat diet-induced non-alcoholic fatty liver disease by inhibiting lipogenesis and promoting anti-oxidation","volume":"13","author":"Ning","year":"2022","journal-title":"Front Pharmacol"},{"key":"ref88","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s12944-022-01689-9","article-title":"Danshao Shugan granule therapy for non-alcoholic fatty liver disease","volume":"21","author":"Wang","year":"2022","journal-title":"Lipids Health Dis"},{"key":"ref89","doi-asserted-by":"publisher","first-page":"153140","DOI":"10.1016\/j.phymed.2019.153140","article-title":"Protective effect of Hedansanqi Tiaozhi Tang against non-alcoholic fatty liver disease in vitro and in vivo through activating Nrf2\/ho-1 antioxidant signaling pathway","volume":"67","author":"Qiu","year":"2020","journal-title":"Phytomedicine"},{"key":"ref90","doi-asserted-by":"publisher","first-page":"530","DOI":"10.3389\/fphar.2020.00530","article-title":"Si-Wei-Qing-Gan-Tang improves non-alcoholic steatohepatitis by modulating the nuclear factor-\u039ab signal pathway and autophagy in methionine and choline deficient diet-fed rats","volume":"11","author":"Xiao","year":"2020","journal-title":"Front Pharmacol"},{"key":"ref91","doi-asserted-by":"publisher","first-page":"116967","DOI":"10.1016\/j.jep.2023.116967","article-title":"Chaihu Shugan powder influences nonalcoholic fatty liver disease in rats in remodeling micrornaome and decreasing fatty acid synthesis","volume":"318","author":"Zheng","year":"2024","journal-title":"J Ethnopharmacol"},{"key":"ref92","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.14218\/jcth.2021.00458","article-title":"Quzhi formula alleviates nonalcoholic steatohepatitis by impairing hepatocyte lipid accumulation and inflammation via Bip\/Eif2\u03b1 signaling","volume":"10","author":"Wu","year":"2022","journal-title":"J Clin Transl Hepatol"},{"key":"ref93","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.jtcme.2023.02.010","article-title":"Yinchenhao Tang alleviates high fat diet induced Nafld by increasing Nr1h4 and Apoa1 expression","volume":"13","author":"Xu","year":"2023","journal-title":"J Tradit Complement Med"},{"key":"ref94","doi-asserted-by":"publisher","first-page":"116933","DOI":"10.1016\/j.jep.2023.116933","article-title":"Protective effects of Scutellaria-Coptis herb couple against non-alcoholic steatohepatitis via activating Nrf2 and Fxr pathways in vivo and in vitro","volume":"318","author":"Xue","year":"2024","journal-title":"J Ethnopharmacol"},{"key":"ref95","doi-asserted-by":"publisher","first-page":"1016745","DOI":"10.3389\/fphar.2022.1016745","article-title":"Shuangyu Tiaozhi decoction alleviates non-alcoholic fatty liver disease by improving lipid deposition, insulin resistance, and inflammation in vitro and in vivo","volume":"13","author":"Yin","year":"2022","journal-title":"Front Pharmacol"},{"key":"ref96","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13020-021-00559-3","article-title":"Traditional Chinese medicine Lingguizhugan decoction ameliorate Hfd-induced hepatic-lipid deposition in mice by inhibiting Sting-mediated inflammation in macrophages","volume":"17","author":"Cao","year":"2022","journal-title":"Chin Med"},{"key":"ref97","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1080\/13880209.2021.1979594","article-title":"Jiang Zhi granule protects immunological barrier of intestinal mucosa in rats with non-alcoholic steatohepatitis","volume":"59","author":"Yu","year":"2021","journal-title":"Pharm Biol"},{"key":"ref98","doi-asserted-by":"publisher","first-page":"116988","DOI":"10.1016\/j.jep.2023.116988","article-title":"The identification of material basis of Si Miao formula effective for attenuating non-alcoholic fatty liver disease","volume":"318","author":"Li","year":"2024","journal-title":"J Ethnopharmacol"},{"key":"ref99","doi-asserted-by":"publisher","first-page":"153544","DOI":"10.1016\/j.phymed.2021.153544","article-title":"Si Miao formula attenuates non-alcoholic fatty liver disease by modulating hepatic lipid metabolism and gut microbiota","volume":"85","author":"Han","year":"2021","journal-title":"Phytomedicine"},{"key":"ref100","doi-asserted-by":"publisher","first-page":"116811","DOI":"10.1016\/j.jep.2023.116811","article-title":"Erchen decoction alleviates obesity-related hepatic steatosis via modulating gut microbiota-drived butyric acid contents and promoting fatty acid \u0392-oxidation","volume":"317","author":"Zhang","year":"2023","journal-title":"J Ethnopharmacol"},{"key":"ref101","doi-asserted-by":"publisher","first-page":"984019","DOI":"10.3389\/fmicb.2022.984019","article-title":"Tianhuang formula reduces the oxidative stress response of Nafld by regulating the gut microbiome in mice","volume":"13","author":"Luo","year":"2022","journal-title":"Front Microbiol"},{"key":"ref102","doi-asserted-by":"publisher","first-page":"116665","DOI":"10.1016\/j.jep.2023.116665","article-title":"Qing-Zhi-Tiao-Gan-Tang (Qztgt) prevents nonalcoholic steatohepatitis (Nash) by expression pattern correction","volume":"317","author":"Chu","year":"2023","journal-title":"J Ethnopharmacol"},{"key":"ref103","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s13020-021-00434-1","article-title":"Hepatoprotective effect of Qushihuayu formula on non-alcoholic steatohepatitis induced by mcd diet in rat","volume":"16","author":"Lan","year":"2021","journal-title":"Chin Med"},{"key":"ref104","doi-asserted-by":"publisher","first-page":"113076","DOI":"10.1016\/j.biopha.2022.113076","article-title":"The anti-inflammatory effect of Pien Tze Huang in non-alcoholic fatty liver disease","volume":"151","author":"Lian","year":"2022","journal-title":"Biomed Pharmacother"},{"key":"ref105","doi-asserted-by":"publisher","first-page":"56","DOI":"10.16305\/j.1007-1334.2019.02.015","article-title":"Clinical study on treatment of non-alcoholic fatty liver disease of phlegm-blood stasis type with Qinjiang Baoling decoction","volume":"53","author":"Minxin","year":"2019","journal-title":"Shanghai J Tradit Chin Med"},{"key":"ref106","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.13288\/j.11-2166\/r.2023.14.008","article-title":"Treatment of non-alcoholic fatty liver disease with spleen deficiency and binding of phlegm and stasis syndrome by Lanzhang granules: a randomized controlled study","volume":"64","author":"Nan","year":"2023","journal-title":"J Tradit Chin Med"},{"key":"ref107","doi-asserted-by":"publisher","first-page":"1107071","DOI":"10.3389\/fendo.2022.1107071","article-title":"The spleen-strengthening and liver-draining herbal formula treatment of non-alcoholic fatty liver disease by regulation of intestinal Flora in clinical trial","volume":"13","author":"Hui","year":"2022","journal-title":"Front Endocrinol"},{"key":"ref108","doi-asserted-by":"publisher","first-page":"594","DOI":"10.13288\/j.11-2166\/r.2018.07.014","article-title":"Evaluating the clinical effect of modified Shugan Xiaozhi decoction in treating nonalcoholic fatly liver disease based on Fibroscan technique","volume":"59","author":"Haihong","year":"2018","journal-title":"J Tradit Chin Med"},{"key":"ref109","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.11842\/wst.20180922007","article-title":"Clinical study on phlegm-obstruction type of Nafld patients with the treatment of Qinghua decoction","volume":"21","author":"Shuang","year":"2019","journal-title":"Moder Trad Chinese Med Mater Med World Sci Technol"},{"key":"ref110","doi-asserted-by":"publisher","first-page":"745","DOI":"10.13288\/j.11-2166\/r.2022.08.010","article-title":"The effect of Qingre Huashi formula on chronic hepatitis B or nonalcoholic fatty liver disease with damp-heat syndrome: a multicenter randomized double-blind placebo-controlled trial","volume":"63","author":"Chaoqun","year":"2022","journal-title":"J Tradit Chin Med"},{"key":"ref111","doi-asserted-by":"publisher","first-page":"66","DOI":"10.13862\/j.cnki.cn43-1446\/r.2022.02.036","article-title":"Clinical observation of self-proposed Xiaopi Huatan granules combined with Silibinin capsules in the treatment of non-alcoholic steatohepatitis with phlegm-damp internal resistance syndrome","volume":"28","author":"Shuangshuang","year":"2022","journal-title":"Guid J Trad Chinese Med Pharm"},{"key":"ref112","doi-asserted-by":"publisher","first-page":"78","DOI":"10.13193\/j.issn.1673-7717.2020.11.021","article-title":"Clinical observation of Zhibitai capsule on nonalcoholic fatty liver disease","volume":"38","author":"Zhe","year":"2020","journal-title":"Chin Arch Tradit Chin Med"},{"key":"ref113","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1007\/s11684-021-0880-3","article-title":"Lingguizhugan decoction, a Chinese herbal formula, improves insulin resistance in overweight\/obese subjects with non-alcoholic fatty liver disease: a translational approach","volume":"16","author":"Dai","year":"2022","journal-title":"Front Med"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1476419\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T04:33:08Z","timestamp":1728361988000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1476419\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,8]]},"references-count":113,"alternative-id":["10.3389\/fmed.2024.1476419"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2024.1476419","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,8]]},"article-number":"1476419"}}